#USA #San Francisco #AI Technology #oncology #DeepScribe

DeepScribe's Impact on Oncology

In the rapidly evolving field of oncology, DeepScribe emerges as a leading force in ambient AI technology designed specifically for cancer care. Recently, the company announced a significant milestone: its AI is set to document over 3.1 million cancer care visits annually. This achievement is attributed to the increasing adoption rates and the technology's seamless integration into existing workflows in community oncology.

Accelerating Growth and User Adoption

Since August, the volume of oncology visits documented with DeepScribe has doubled, and it has quadrupled since January 2025. This surge can largely be credited to the user-friendly nature of the AI, which enhances efficiency for both healthcare providers and patients. The integration of DeepScribe into oncology-specific Electronic Medical Records (EMRs) facilitates smoother operations, allowing oncologists to focus more on patient care rather than administrative tasks.

Transforming Clinical Experience

Matthew Ko, the founder and CEO of DeepScribe, emphasized the original vision behind the AI technology, noting that it was designed to alleviate the administrative burden on oncologists. By focusing specifically on oncology's complexities, DeepScribe's ambient AI offers a sophisticated documentation tool that accurately captures patient care.

This innovative approach has led to a trust factor that fosters widespread adoption—more than 95% of recent deployments are reported to have embraced DeepScribe's capabilities. Indeed, DeepScribe currently supports roughly 40% of all cancer visits across the U.S., offering rich documentation and insights that allow for a more comprehensive understanding of patient needs.

Recognition and Impact

In October 2025, KLAS Research highlighted DeepScribe's success by awarding it three Top 5 positions in categories reflecting improvements in outcomes and experiences for both clinicians and patients. Earlier that year, DeepScribe received an impressive performance score of 98.8 out of 100, reinforcing its status as a leader in AI solutions for oncology.

A study published in the Journal of Clinical Pathways underscored DeepScribe's diagnostic impact:

• - 16% increase in diagnoses per visit
• - 22% increase in specificity for ICD-10 codes
• - 22% increase in comorbidities captured
• - 45% increase in social determinants of health data documented

These results demonstrate DeepScribe's efficacy in improving clinical documentation without adding to the workload of clinicians, thus enhancing the overall cancer care landscape.

Looking Ahead

The future looks promising for DeepScribe, as it continues to expand its presence among major oncology organizations such as Texas Oncology and New York Cancer & Blood Specialists. With a clear trajectory of growth, the company plans to innovate further, developing their Ambient Operating System to cater to evolving oncological needs. Future initiatives aim to create structured datasets that can facilitate real-time insights for clinical trial matching, biomarker identification, and optimized treatment planning.

Conclusion

DeepScribe's journey from its inception in 2017 to its current leadership role in oncology AI is marked by a commitment to enhancing the quality of patient care. As it continues to evolve, DeepScribe stands at the forefront of a transformation in how cancer documentation is approached, ensuring that healthcare professionals can devote more time to what truly matters—caring for their patients. For further insights into DeepScribe's innovations and the joy they bring back into medicine, visit their official website at deepscribe.ai.